Vanda Pharmaceuticals | VNDA - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Acadia Pharmaceuticals USD 851.46M 31.77M 2026-03
Agios Pharmaceuticals USD 113.6M 24.47M 2026-03
Akebia Therapeutics USD 162.64M 22.2M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Anika Therapeutics USD 41.02M 16.46M 2026-03
Arrowhead Research USD 201.64M 112.94M 2025-12
AstraZeneca USD 7.56B 1.85B 2026-03
Bristol-Myers Squibb USD 9.57B 635M 2026-03
Eli Lilly USD 5.28B 1.99B 2026-03
Enanta Pharmaceuticals USD 37.44M 5.14M 2025-12
Esperion Therapeutics USD 156.16M 11.69M 2026-03
Halozyme Therapeutics USD 309.75M 175.93M 2026-03
Heron Therapeutics USD 26.12M 2.53M 2026-03
Insmed USD 582.19M 71.74M 2026-03
J&J USD 21.69B 1.98B 2026-03
Lexicon Pharmaceuticals USD 38.09M 3.76M 2026-03
Ligand Pharmaceuticals USD 115.08M 59.85M 2026-03
Merck USD 5.33B 9.24B 2026-03
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 1.91B 687M 2026-03
Novartis USD 6.88B 2.68B 2026-03
Pfizer USD 1.7B 561M 2026-03
PTC Therapeutics USD 833.99M 150.66M 2026-03
Puma Biotechnology USD 53.52M 1.14M 2025-09
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Takeda JPY 654.94B 26.55B 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Veracyte USD 263.14M 99.44M 2026-03